-Search query
-Search result
Showing 1 - 50 of 81 items for (author: higuchi & y)
EMDB-37648:
SARS-CoV-2 EG.5.1 spike glycoprotein (1-up state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
EMDB-37650:
SARS-CoV-2 EG.5.1 spike glycoprotein (closed-2 state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
EMDB-37651:
SARS-CoV-2 EG.5.1 spike glycoprotein (closed-1 state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
PDB-8wmd:
Structure of the SARS-CoV-2 EG.5.1 spike glycoprotein (closed-2 state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
PDB-8wmf:
Structure of the SARS-CoV-2 EG.5.1 spike glycoprotein (closed-1 state)
Method: single particle / : Nomai T, Anraku Y, Kita S, Hashiguchi T, Maenaka K
EMDB-17104:
AApoAII amyloid fibril Morphology II (ex vivo)
Method: helical / : Andreotti G, Schmidt M, Faendrich M
EMDB-17105:
AApoAII amyloid fibril Morphology I (ex vivo)
Method: helical / : Andreotti G, Schmidt M, Faendrich M
PDB-8oq4:
AApoAII amyloid fibril Morphology II (ex vivo)
Method: helical / : Andreotti G, Schmidt M, Faendrich M
PDB-8oq5:
AApoAII amyloid fibril Morphology I (ex vivo)
Method: helical / : Andreotti G, Schmidt M, Faendrich M
EMDB-36724:
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 1)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36726:
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 2)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36727:
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36728:
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (2-up state)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-36729:
Structure of SARS-CoV-2 XBB.1.5 spike RBD in complex with ACE2
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8jyk:
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 1)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8jym:
Structure of the SARS-CoV-2 XBB.1.5 spike glycoprotein (closed state 2)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8jyn:
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (1-up state)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8jyo:
Structure of SARS-CoV-2 XBB.1.5 spike glycoprotein in complex with ACE2 (2-up state)
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
PDB-8jyp:
Structure of SARS-CoV-2 XBB.1.5 spike RBD in complex with ACE2
Method: single particle / : Yajima H, Anraku Y, Kita S, Kimura K, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
EMDB-35029:
SARS-CoV2 spike protein with ACE2, no ACE2 binding.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35030:
SARS-CoV2 spike protein with ACE2. 1 ACE2 bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35031:
SARS-CoV2 spike protein with ACE2. 2 ACE2 bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35032:
SARS-CoV2 spike protein with ACE2. 3 ACE2 bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35036:
SARS-CoV2 spike protein with ACE2 decoy.no ACE2 decoy binding
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35037:
SARS-CoV2 spike protein with ACE2 decoy. 1 ACE2 decoy bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35038:
SARS-CoV2 spike protein with ACE2 decoy. 1 ACE2 decoy bound and 2 RBD up form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35039:
SARS-CoV2 spike protein with ACE2 decoy. 2 ACE2 decoy bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-35040:
SARS-CoV2 spike protein with ACE2 decoy. 3 ACE2 decoy bound form.
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-36345:
RBD of SARS-CoV2 spike protein with ACE2 decoy
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
PDB-8jje:
RBD of SARS-CoV2 spike protein with ACE2 decoy
Method: single particle / : Kishikawa J, Hirose M, Kato T, Okamoto T
EMDB-36905:
SARS-CoV-2 BA.1 RBD with UT28-RD
Method: single particle / : Chen L, Kita S, Anraku Y, Maenaka K
EMDB-36906:
SARS-CoV-2 BA.1 spike with UT28-RD
Method: single particle / : Chen L, Kita S, Anraku Y, Maenaka K
EMDB-34741:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-34742:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 focused on RBD and NIV-11 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgl:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgm:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33820:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 focused on RBD and NIV-8 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33821:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33822:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33823:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 focused on RBD and NIV-10 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33824:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33825:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33826:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33827:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 focused on RBD and NIV-13 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33828:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33829:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33830:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh6:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh7:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-35622:
SARS-CoV-2 XBB.1 spike glycoprotein (closed-1 state)
Method: single particle / : Anraku Y, Kita S, Yajima H, Sasaki J, Sasaki-Tabata K, Maenaka K, Hashiguchi T
Pages: